ResearcherNingbo UniversityActive in the last 2 years
Tao Xia
Matched on ORCID iD 0000-0003-3014-4825; OpenAlex author ID A5047100994. Sources: OpenAlex.
Their work
- Papers
- 7
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 53
2017: 1 paper · 2018: none · 2019: none · 2020: none · 2021: 1 paper · 2022: 1 paper · 2023: none · 2024: 2 papers · 2025: 1 paper · 2026: 1 paper
Papers 7
- Propionyl-CoA catabolism is a metabolic gatekeeper for fatty acid oxidation in pancreatic cancer. Co-author DOI 10.1038/s41388-026-03979-3↗
- Phase 1 trial of HR070803 (an Irinotecan liposome) in combination with 5-fluorouracil, leucovorin, and oxaliplatin for untreated advanced or metastatic pancrea… Co-author DOI 10.1186/s12916-025-04234-4↗
- Irinotecan hydrochloride liposome HR070803 in combination with 5-fluorouracil and leucovorin in locally advanced or metastatic pancreatic ductal adenocarcinoma… Co-author DOI 10.1038/s41392-024-01948-4↗
- Neoadjuvant radioimmunotherapy in pancreatic cancer enhances effector T cell infiltration and shortens their distances to tumor cells. Co-author DOI 10.1126/sciadv.adk1827↗
- Multi-omic analyses of changes in the tumor microenvironment of pancreatic adenocarcinoma following neoadjuvant treatment with anti-PD-1 therapy. Co-author DOI 10.1016/j.ccell.2022.10.001↗
- MicroRNAs as biomarkers and perspectives in the therapy of pancreatic cancer. Co-author DOI 10.1007/s11010-021-04233-y↗
- Stromal Annexin A2 expression is predictive of decreased survival in pancreatic cancer. Co-author DOI 10.18632/oncotarget.22433↗
Closest collaborators
The 25 strongest of 53 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Elizabeth M. Jaffee · 3 shared papers, 2017–2024 · strength 0.34
- Paper Neoadjuvant radioimmunotherapy in pancreatic cancer enhances effector T cell infiltration and shortens their distances … DOI 10.1126/sciadv.adk1827↗
- Paper Multi-omic analyses of changes in the tumor microenvironment of pancreatic adenocarcinoma following neoadjuvant treatme… DOI 10.1016/j.ccell.2022.10.001↗
- Paper Stromal Annexin A2 expression is predictive of decreased survival in pancreatic cancer. DOI 10.18632/oncotarget.22433↗
- Lei Zheng · 3 shared papers, 2017–2024 · strength 0.34
- Paper Neoadjuvant radioimmunotherapy in pancreatic cancer enhances effector T cell infiltration and shortens their distances … DOI 10.1126/sciadv.adk1827↗
- Paper Multi-omic analyses of changes in the tumor microenvironment of pancreatic adenocarcinoma following neoadjuvant treatme… DOI 10.1016/j.ccell.2022.10.001↗
- Paper Stromal Annexin A2 expression is predictive of decreased survival in pancreatic cancer. DOI 10.18632/oncotarget.22433↗
- Zhihua Li · 2 shared papers, 2024–2025 · strength 0.33
- Paper Phase 1 trial of HR070803 (an Irinotecan liposome) in combination with 5-fluorouracil, leucovorin, and oxaliplatin for … DOI 10.1186/s12916-025-04234-4↗
- Paper Irinotecan hydrochloride liposome HR070803 in combination with 5-fluorouracil and leucovorin in locally advanced or met… DOI 10.1038/s41392-024-01948-4↗
- Deliang Fu · 2 shared papers, 2024–2025 · strength 0.33
- Paper Phase 1 trial of HR070803 (an Irinotecan liposome) in combination with 5-fluorouracil, leucovorin, and oxaliplatin for … DOI 10.1186/s12916-025-04234-4↗
- Paper Irinotecan hydrochloride liposome HR070803 in combination with 5-fluorouracil and leucovorin in locally advanced or met… DOI 10.1038/s41392-024-01948-4↗
- Xiaojun Ren · 1 shared paper, 2026 · strength 0.27
- Weidong Yu · 1 shared paper, 2026 · strength 0.27
- Hongwei Sun · 1 shared paper, 2026 · strength 0.27
- Wei Cui · 1 shared paper, 2026 · strength 0.27
- Hezhi Fang · 1 shared paper, 2026 · strength 0.27
- Robert A. Anders · 2 shared papers, 2022–2024 · strength 0.26
- Paper Neoadjuvant radioimmunotherapy in pancreatic cancer enhances effector T cell infiltration and shortens their distances … DOI 10.1126/sciadv.adk1827↗
- Paper Multi-omic analyses of changes in the tumor microenvironment of pancreatic adenocarcinoma following neoadjuvant treatme… DOI 10.1016/j.ccell.2022.10.001↗
- Jin Peng He · 2 shared papers, 2022–2024 · strength 0.26
- Paper Neoadjuvant radioimmunotherapy in pancreatic cancer enhances effector T cell infiltration and shortens their distances … DOI 10.1126/sciadv.adk1827↗
- Paper Multi-omic analyses of changes in the tumor microenvironment of pancreatic adenocarcinoma following neoadjuvant treatme… DOI 10.1016/j.ccell.2022.10.001↗
- Keyu Li · 2 shared papers, 2022–2024 · strength 0.26
- Paper Neoadjuvant radioimmunotherapy in pancreatic cancer enhances effector T cell infiltration and shortens their distances … DOI 10.1126/sciadv.adk1827↗
- Paper Multi-omic analyses of changes in the tumor microenvironment of pancreatic adenocarcinoma following neoadjuvant treatme… DOI 10.1016/j.ccell.2022.10.001↗
- Tengyi Zhang · 2 shared papers, 2022–2024 · strength 0.26
- Paper Neoadjuvant radioimmunotherapy in pancreatic cancer enhances effector T cell infiltration and shortens their distances … DOI 10.1126/sciadv.adk1827↗
- Paper Multi-omic analyses of changes in the tumor microenvironment of pancreatic adenocarcinoma following neoadjuvant treatme… DOI 10.1016/j.ccell.2022.10.001↗
- Arsen Osipov · 2 shared papers, 2022–2024 · strength 0.26
- Paper Neoadjuvant radioimmunotherapy in pancreatic cancer enhances effector T cell infiltration and shortens their distances … DOI 10.1126/sciadv.adk1827↗
- Paper Multi-omic analyses of changes in the tumor microenvironment of pancreatic adenocarcinoma following neoadjuvant treatme… DOI 10.1016/j.ccell.2022.10.001↗
- Amol Kumar Narang · 2 shared papers, 2022–2024 · strength 0.26
- Paper Neoadjuvant radioimmunotherapy in pancreatic cancer enhances effector T cell infiltration and shortens their distances … DOI 10.1126/sciadv.adk1827↗
- Paper Multi-omic analyses of changes in the tumor microenvironment of pancreatic adenocarcinoma following neoadjuvant treatme… DOI 10.1016/j.ccell.2022.10.001↗
- Daniel A. Laheru · 2 shared papers, 2022–2024 · strength 0.26
- Paper Neoadjuvant radioimmunotherapy in pancreatic cancer enhances effector T cell infiltration and shortens their distances … DOI 10.1126/sciadv.adk1827↗
- Paper Multi-omic analyses of changes in the tumor microenvironment of pancreatic adenocarcinoma following neoadjuvant treatme… DOI 10.1016/j.ccell.2022.10.001↗
- You-Ni Zhang · 1 shared paper, 2021 · strength 0.22
- Huan Wang · 1 shared paper, 2025 · strength 0.18
- Xue Yang · 1 shared paper, 2025 · strength 0.18
- Xiaoyu Yin · 1 shared paper, 2025 · strength 0.18
- Tongsen Zheng · 1 shared paper, 2025 · strength 0.18
- Xianze Wang · 1 shared paper, 2025 · strength 0.18
- Qiang Xu · 1 shared paper, 2025 · strength 0.18
- Chuntao Gao · 1 shared paper, 2025 · strength 0.18
- Yuejuan Cheng · 1 shared paper, 2025 · strength 0.18
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.